Evaluating Delta-8-THC-Induced Psychosis: A Systematic Review

Area of Science:

• Psychiatry
• Cannabinoid Science
• Public Health

Background:

• Increasing legalization of marijuana has led to wider use of cannabinoids.
• Delta-9-THC is known for psychoactive effects and psychosis induction.
• Delta-8-THC is gaining popularity but is under-researched regarding its psychiatric effects.

Purpose of the Study:

• To review existing literature on the psychiatric effects of delta-8-THC.
• To highlight the association between delta-8-THC use and severe mental health outcomes, particularly psychosis.
• To underscore the need for further research and regulatory oversight.

Main Methods:

• A systematic literature search was conducted using PubMed and Web of Science, adhering to PRISMA guidelines.
• Studies specifically on delta-8-THC and psychosis were included; articles on other cannabinoids were excluded.
• Case reports were critically appraised using the Critical Appraisal Skills Programme Checklist.

Main Results:

• Twelve studies, including six case reports involving nine patients, met the inclusion criteria.
• Patients, predominantly young males, presented with psychosis, mood lability, and cannabinoid hyperemesis syndrome.
• Reported psychiatric histories varied, including no prior conditions, schizophrenia, PTSD, and generalized anxiety disorder.

Conclusions:

• Delta-8-THC presents significant psychiatric risks, including psychosis, despite being less intoxicating than delta-9-THC.
• Lack of FDA regulation and widespread availability of delta-8-THC products exacerbate these risks.
• More comprehensive research is essential to understand delta-8-THC's mental health impact and guide regulatory measures.